Taysha Q3 net loss $25.5M; TSHA-102 high dose safe; FDA aligns on pivotal trial design

Taysha Gene Therapies, Inc.

2024-Q3 EPS reported -$0.29 revenue$6,311,000

Net loss $25.5M ($0.10/sh) vs $117.1M loss in Q3 2023; cash $157.7M into Q4 2026.
High dose TSHA-102 well tolerated; no SAEs or DLTs in 2 adolescent/adult and 1 pediatric patient.
FDA aligned on trial design, endpoints, and natural history dataset for Part B of REVEAL trials.
FDA approved pivotal TSHA-102 product manufactured with final commercial manufacturing process for REVEAL trials.
Safety and efficacy data from high dose cohorts of both REVEAL trials expected H1 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.